RSV concerns abound as FDA considers vaccines; leaked study results show big benefits to J&J CAR-T drug

Taking stock of the drug industry, from the lab to the medicine chest

April 19, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

NIAID STAT+ | STAT-Harris Poll: Most Americans are worried about RSV The survey found that 71% of Americans who are familiar with the virus are concerned their children may contract RSV. By Ed Silverman STAT+ | Leaked study results show a CAR-T from J&J providing big benefit for patients with multiple myeloma Carvykti, made with Legend Biotech, reduced the risk of relapse by 74% compared to standard treatment in patients with multiple myeloma. By Adam Feuerstein Supreme Court delays ruling on abortion pill restrictions The Supreme Court has delayed its ruling on whether the abortion pill mifepristone can remain on the market. By Sarah Owermohle National Cancer Institute/Massey Cancer Center at Virginia Commonwealth Univ. STAT+ | Relay's breast cancer drug proves tolerable, but market is unimpressed The drug attacked mutations precisely, without causing a common toxic side effect. But it did little to shrink tumors. By Angus Chen Opinion: RSV vaccine approval should be a top priority for the FDA RSV results in more pediatric hospitalization than any other single cause. Why is the FDA taking so long to approve effective vaccines? By Sallie Permar and Karen Acker Opinion: The window is closing to stop deadly drug-resistant fungi like Candida auris The C. auris outbreak is alarming. But even scarier are the issues it highlights: the lack of fungus surveillance and overuse of antifungals. By Matthew Wellington and Lance Price

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser